Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001 Fall;7(3):317-45.
doi: 10.1111/j.1527-3458.2001.tb00202.x.

Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain

Affiliations
Review

Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain

J Knoll. CNS Drug Rev. 2001 Fall.

Abstract

Hundreds of millions of people now die over the age of 80 years primarily due to twentieth century progress in hygiene, chemotherapy, and immunology. With a longer average lifespan, the need to improve quality of life during the latter decades is more compelling. "Aging--The Epidemic of the New Millenium," a recent international conference (Monte Carlo, June 17-18, 2000), showed with peculiar clarity that a safe and efficient drug strategy to slow the age-related decay of brain performance is still missing. This review summarizes the physiologic and pharmacologic arguments in favor of a peculiar lifelong prophylactic medication with reasonable chances to keep in check brain aging and decrease the precipitation of age-related neurological diseases.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Agnoli A, Fabbrini G, Fioravanti M, Martucci N. CBF and cognitive evaluation of Alzheimer‐type patients before and after MAO‐B treatment: A pilot study. Eur Neuropsychopharmacol 1992;2:31–35. - PubMed
    1. Allain H, Gougnard J, Naukirek HC. Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMP). Acta Neurol Scand 1991;136:73–78. - PubMed
    1. Archer JR, Harrison DE. L‐Deprenyl treatment in aged mice slightly increases lifespans and greatly reduces fecundity by aged males. J Gerontol Sci 1996;13A:B448–B453. - PubMed
    1. Birkmayer W, Hornykiewicz O. Der L‐Dioxyphenyl‐alanin‐Effekt beim Parkinson Syndrom des Menschen. Arch Psychiat Nervenkrh 1962;203:560–564.
    1. Birkmayer W, Riederer P. Parkinson's Disease. Biochemistry, Clinical Pathology and Treatment. New York : Springer‐Verlag, 1983:1–194.